These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30575560)

  • 1. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial.
    Maughan BL; Pal SK; Gill D; Boucher K; Martin C; Salgia M; Nussenzveig R; Liu T; Hawks JL; Batten J; Nachaegari G; Stephenson R; Lowrance W; Jones J; Dechet C; Agarwal N
    Oncologist; 2018 Dec; 23(12):1413-e151. PubMed ID: 30575560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer.
    Pal SK; Vuong W; Zhang W; Deng J; Liu X; Carmichael C; Ruel N; Pinnamaneni M; Twardowski P; Lau C; Yu H; Figlin RA; Agarwal N; Jones JO
    Mol Cancer Ther; 2015 Dec; 14(12):2896-900. PubMed ID: 26450920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy.
    Fujita K; Nakayama M; Nakai Y; Takayama H; Nishimura K; Ujike T; Nishimura K; Aozasa K; Okuyama A; Nonomura N
    Cancer Sci; 2009 Jun; 100(6):1047-50. PubMed ID: 19385972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
    Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
    Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
    Hamberg P; Boers-Sonderen MJ; van der Graaf WT; de Bruijn P; Suttle AB; Eskens FA; Verweij J; van Herpen CM; Sleijfer S
    Br J Cancer; 2014 Feb; 110(4):888-93. PubMed ID: 24366297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
    Sloan B; Scheinfeld NS
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1324-35. PubMed ID: 19037839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
    Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.
    Talagas M; Uguen A; Garlantezec R; Fournier G; Doucet L; Gobin E; Marcorelles P; Volant A; DE Braekeleer M
    Anticancer Res; 2013 May; 33(5):2065-75. PubMed ID: 23645757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib in the treatment of soft tissue sarcoma.
    Schöffski P
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
    Ward JE; Karrison T; Chatta G; Hussain M; Shevrin D; Szmulewitz RZ; O'Donnell PH; Stadler WM; Posadas EM
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):87-92. PubMed ID: 22006050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
    J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
    Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
    Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
    Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
    Melichar B; Studentová H; Zezulová M
    J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
    Hamberg P; Verweij J; Sleijfer S
    Oncologist; 2010; 15(6):539-47. PubMed ID: 20511320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib in ovarian cancer.
    McLachlan J; Banerjee S
    Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.